levodopa/benserazide 50/12.5 pch, capsules 50/12.5 mg
central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - levodopa, benserazide hydrochloride - capsule - levodopa 50 mg benserazide hydrochloride 12.5 mg - anti-parkinson drugs
levodopa/benserazide 50/12.5 pch, capsules 50/12.5 mg
central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - levodopa, benserazide hydrochloride - capsule - levodopa 50 mg benserazide hydrochloride 12.5 mg - anti-parkinson drugs
stalevo 7518.75200
inovamed pharma ltd, israel - carbidopa as monohydrate; entacapone; levodopa - film coated tablets - carbidopa as monohydrate 18.75 mg; entacapone 200 mg; levodopa 75 mg - levodopa - levodopa - treatment of patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa/decarboxylase (ddc) inhibitor treatment.
stalevo 125/31.25/200 levodopa/carbidopa (as monohydrate)/entacapone tablet bottle
sandoz pty ltd - levodopa, quantity: 125 mg; entacapone, quantity: 200 mg; carbidopa monohydrate, quantity: 33.8 mg (equivalent: carbidopa, qty 31.25 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; maize starch; mannitol; povidone; glycerol; hypromellose; polysorbate 80; iron oxide red; sucrose; titanium dioxide - stalevo is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.
stalevo 75/18.75/200 levodopa/carbidopa (as monohydrate)/entacapone tablet bottle
sandoz pty ltd - levodopa, quantity: 75 mg; entacapone, quantity: 200 mg; carbidopa monohydrate, quantity: 20.25 mg (equivalent: carbidopa, qty 18.75 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; maize starch; mannitol; povidone; glycerol; hypromellose; polysorbate 80; iron oxide red; sucrose; titanium dioxide - stalevo is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.
stalevo 200/50/200 levodopa/carbidopa (as monohydrate)/entacapone tablet bottle
sandoz pty ltd - levodopa, quantity: 200 mg; entacapone, quantity: 200 mg; carbidopa monohydrate, quantity: 54.1 mg (equivalent: carbidopa, qty 50 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; maize starch; mannitol; povidone; glycerol; hypromellose; polysorbate 80; iron oxide red; sucrose; titanium dioxide - stalevo is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.
l.c.e. sandoz 50/12.5/200 levodopa 50 mg, carbidopa (as carbidopa monohydrate) 12.5 mg and entacapone 200 mg film-coated tablet bottle
sandoz pty ltd - levodopa, quantity: 50 mg; carbidopa monohydrate, quantity: 13.5 mg (equivalent: carbidopa, qty 12.5 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: hypromellose; mannitol; titanium dioxide; magnesium stearate; povidone; maize starch; sucrose; iron oxide red; glycerol; iron oxide yellow; polysorbate 80; croscarmellose sodium - l.c.e. sandoz 50/12.5/200 is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.
sinemet cr levodopa/carbidopa 200 mg/50 mg modified release tablet bottle
organon pharma pty ltd - carbidopa monohydrate, quantity: 54 mg (equivalent: carbidopa, qty 50 mg); levodopa, quantity: 200 mg - tablet, modified release - excipient ingredients: indigo carmine; hypromellose; hyprolose; allura red ac; magnesium stearate - idiopathic parkinsonism, where standard formulations containing levodopa/carbidopa have produced inadequate control. experience is limited with sinemet cr in patients who have not been treated with levodopa before.
levodopa/carbidopa genpar 250/25 levodopa 250 mg and carbidopa (as monohydrate) 25 mg tablet blister pack
arrotex pharmaceuticals pty ltd - levodopa, quantity: 250 mg; carbidopa monohydrate, quantity: 27 mg (equivalent: carbidopa, qty 25 mg) - tablet, uncoated - excipient ingredients: magnesium stearate; indigo carmine aluminium lake; microcrystalline cellulose; pregelatinised maize starch; crospovidone - levodopa/carbidopa genpar is indicated for the treatment of parkinson's disease and syndrome. it is useful in relieving many of the symptoms of parkinsonism, particularly rigidity and bradykinesia. levodopa/carbidopa genpar frequently is helpful in the management of tremor, dysphagia, sialorrhoea and postural instability associated with parkinson's disease and syndrome.
levodopa/carbidopa genpar 100/25 levodopa 100 mg and carbidopa (as monohydrate) 25 mg tablet blister pack
arrotex pharmaceuticals pty ltd - levodopa, quantity: 100 mg; carbidopa monohydrate, quantity: 27 mg (equivalent: carbidopa, qty 25 mg) - tablet, uncoated - excipient ingredients: pregelatinised maize starch; crospovidone; quinoline yellow aluminium lake; microcrystalline cellulose; magnesium stearate - levodopa/carbidopa genpar is indicated for the treatment of parkinson's disease and syndrome. it is useful in relieving many of the symptoms of parkinsonism, particularly rigidity and bradykinesia. levodopa/carbidopa genpar frequently is helpful in the management of tremor, dysphagia, sialorrhoea and postural instability associated with parkinson's disease and syndrome.